Company / Cash & Equivalents
Stoke Therapeutics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$84.2M
FY2025
5-year range
$84.2M / $191.4M
FY2021-FY2025
Trend
-34.2%
vs FY2024
Sector context
#154 of 207
Health Care
What the data says
At $84M, Stoke Therapeutics, Inc.'s cash & equivalents ranks #154 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 8 years, ranging from $84M in FY2025 to $287M in FY2020.
Based on SEC 10-K filings.
$84M in FY2025 with a 5-year CAGR of -21.8%.
Declined from $191M to $84M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -9.5%
- 5-Year CAGR
- -21.8%
- 10-Year CAGR
- -
Sector benchmark
#154 of 207 in Health CareTop 74% of 207This company $84.2M Sector average $669.5M
▼
-87.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -21.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 34.2% year-over-year.
- Ranks #154 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.2M | -34.2% |
| FY2024 | $128.0M | -33.1% |
| FY2023 | $191.4M | +68.6% |
| FY2022 | $113.6M | -21.6% |
| FY2021 | $144.9M | -49.6% |
| FY2020 | $287.3M | +29.1% |
| FY2019 | $222.5M | +111.1% |
| FY2018 | $105.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026